Introduction {#s1}
============

Among women in low-, middle-, and high-income countries, breast cancer is the most frequently occurring cancer, with an estimated 2.09 million new cases diagnosed worldwide in 2018 International Agency for Research on Cancer (IARC) and World Health Organization (WHO). Similarly, in Taiwan, breast cancer has been the most prevalent cancer among women for two decades, during which the age-adjusted incidence rate has risen gradually from 55.88 per 100,000 people in 2002 to 89.21 per 100,000 people in 2012 ([@B6]). In the near future, increasing numbers of long-term survivors of breast cancer can be expected because of factors such as effective cancer screening, improved diagnostic tools that enable early detection, improved adjuvant treatments, relatively favorable prognoses with slower progression than most other cancers, and the aging population. As a result, surveillance and follow-up care of such survivors have become pertinent topics, both for the control of the cancer and its treatment-related health conditions ([@B17]).

Meningioma originates in the meningothelial cells of the arachnoid membrane and is the most prevalent primary intracranial neoplasm in adults. Between 2008 and 2012, in the United States, meningioma accounted for 36.4% of all primary tumors occurring in the brain and other organs of the central nervous system ([@B33]). The rate of meningioma incidence in women is nearly two times that in men, especially during the reproductive period of life ([@B8]; [@B44]; [@B33]). Breast cancer in women has been associated with meningioma ([@B16]; [@B27]; [@B37]; [@B30]). Approximately 66% of all breast cancers (and even higher in older women) are hormone receptor--positive ([@B36]; [@B31]). Thus, for most patients, hormone therapy should be considered as an adjuvant to surgery. Evidence suggests that tamoxifen---among the most extensively administered selective estrogen receptor modulators in hormone receptor--positive breast cancer patients---increases disease-free and overall survival rates ([@B28]). Even though tamoxifen is generally well tolerated, with a fair adherence rate ([@B45]), the safety of tamoxifen treatment is of clinical concern ([@B35]). The occurrence of meningioma and tamoxifen use might plausibly be connected; hormonal factors have been proven to be involved in the development of meningioma ([@B18]; [@B43]; [@B25]; [@B24]; [@B5]), and approximately 70% of meningiomas show progesterone receptor expression whereas approximately 30% show estrogen receptor expression ([@B43]). An early study suggested that tamoxifen treatment may prevent the development of meningioma in breast cancer patients ([@B23]).

In the present retrospective cohort study, we used a population-based database derived from Taiwan's National Health Insurance (NHI) system to investigate whether tamoxifen treatment can effectively protect breast cancer survivors against meningioma development and whether the duration or cumulative dosage of tamoxifen treatment affects this possible relationship.

Methods {#s2}
=======

Data Source {#s2_1}
-----------

Taiwan provides medical insurance coverage to 99% of its 23.74 million residents; data regarding medical insurance recipients are stored in the NHI Research Database (NHIRD) (Database NHIR). The Registry for Catastrophic Illness Patient Database (RCIPD), a subset of the NHIRD, was used for this retrospective cohort study. In Taiwan, when patients apply for qualified catastrophic illness certificates, their illnesses must be confirmed by clinical physicians. The RCIPD has been discussed in detail in the literature ([@B34]; [@B19]). The diagnoses in the NHIRD are coded on the basis of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

Study Population {#s2_2}
----------------

In the data for the period from January 1, 2000, to December 31, 2008, we identified women with breast cancer and of age ≥20 years (ICD-9-CM 174). The identified patients were divided into two groups: those who had not received tamoxifen therapy (i.e., the non-tamoxifen cohort or controls) and those who had (i.e., the tamoxifen cohort). The index date in the tamoxifen cohort was set as the day of first tamoxifen treatment. For each patient in the non-tamoxifen cohort, the index date was a randomly selected date with the same index year as that in the tamoxifen cohort. Patients younger than 20 years and those with a history of meningioma (ICD-9-CM 225.2) or other cancers (namely, ICD-9-CM 140-173 and 175-208) prior to the index date were excluded.

Outcome and Comorbidities and Medication {#s2_3}
----------------------------------------

From the index date onward, both cohorts were followed until withdrawal from the NHI program, meningioma occurrence, or December 31, 2011. Patients whose claims records revealed a diagnosis of alcohol-related illness (ICD-9-CM 291, 303, 305, 571.0, 571.1, 571.2, 571.3, 790.3, A215, and V11.3), chronic obstructive pulmonary disease (COPD) (ICD-9-CM: 491, 492, and 496), coronary artery disease (CAD) (ICD-9-CM 410--414), diabetes (ICD-9-CM 250), hypertension (ICD-9-CM 401--405), or stroke (ICD-9-CM 430--438) at the baseline were defined as having comorbidities. The medications included steroids, statins, and thiazide diuretics. In addition, treatment information for breast cancer patients who received surgical operations, aromatase inhibitors, chemotherapy, and radiotherapy was considered in our study.

Statistical Analysis {#s2_4}
--------------------

The distributions of age, comorbidities, drug, and breast cancer treatment were calculated as frequency (relative frequency, %) or mean ± standard deviation. The differences in the data of the two cohorts were analyzed through Student *t* testing for continuous variables and chi-square testing for categorical variables. We used the Kaplan--Meier method to assess the cumulative incidence of meningioma in the tamoxifen and non-tamoxifen cohorts and estimated the differences between the cohorts through log-rank testing. In addition, the incidence density of meningioma per 10,000 person-years was computed for each cohort. Univariable and multivariable Cox proportional hazards models were employed to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) of meningioma in the tamoxifen cohort relative to the non-tamoxifen cohort. Given that during the study period, the patients may have taken tamoxifen irregularly, the calculations here may have underestimated the drug effect. To diminish this bias in estimating the meningioma risk, we employed Cox proportional hazard model with time-dependent exposure covariates. We evaluated the effects of tamoxifen use duration (≤365, 366--1,500, and \>1,500 days) and cumulative dosage (≤4,280, 4,281--12,980, 12,981--26,320, and \>26,320 mg) on the risk of meningioma in patients with breast cancer. Furthermore, we assessed the joint effects of aromatase inhibitor use and tamoxifen use. All data were analyzed using the SAS statistical package (v9.4; SAS Institute Inc., Cary, NC, USA). Any difference with two-tailed *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

[**Table 1**](#T1){ref-type="table"} presents a comparison of the baseline characteristics of the two cohorts. On average, patients in the tamoxifen cohort were younger than those in the non-tamoxifen cohort. The non-tamoxifen cohort had higher proportions of patients with CAD, stroke, hypertension, diabetes, statin use, and thiazide diuretics use. The tamoxifen cohort exhibited higher proportions of breast surgery, radiotherapy, aromatase inhibitor alone, and combined aromatase inhibitor and chemotherapy treatment; however, the non-tamoxifen cohort had a higher proportion of chemotherapy alone.

###### 

Demographic and comorbidity data of breast cancer patients classified by tamoxifen use status.

                                                            Breast cancer   *P* value                                       
  --------------------------------------------------------- --------------- ----------- --------- ------- --------- ------- ---------
  **Variable**                                              ***n***         **%**       ***n***   **%**   ***n***   **%**   
  **Age, years**                                                                                                            \<0.001
   20--44                                                   21,556          26.5        7,075     22.9    14,481    28.7    
   45--64                                                   47,179          58.0        18,588    60.1    28,591    56.7    
   ≥65                                                      12,636          15.5        5,266     17.0    7,370     14.6    
   Means (SD)^a^                                            52.6            11.7        53.7      11.9    51.9      11.6    \<0.001
  **Comorbidity**                                                                                                           
   CAD                                                      10,426          12.8        4,069     13.2    6,357     12.6    0.02
   COPD                                                     6,308           7.75        2,452     7.93    3,856     7.64    0.14
   Stroke                                                   1,901           2.34        891       2.88    1,010     2.00    \<0.001
   Alcohol-related illness                                  1,220           1.50        459       1.48    761       1.51    0.78
   Hypertension                                             23,924          29.4        9,506     30.7    14,418    28.6    \<0.001
   Diabetes                                                 8,092           9.94        3,272     10.6    4,820     9.56    \<0.001
  **Drug**                                                                                                                  
   Steroids                                                 47,754          58.7        18,009    58.2    29,745    59.0    0.04
   Statins                                                  10,349          12.7        4,375     14.2    5,974     11.8    \<0.001
   Thiazide diuretics                                       19,215          23.6        7,785     25.2    11,430    22.7    \<0.001
  Treatment I = local therapy                                                                                               
  Breast surgery                                            70,120          86.2        25,122    81.2    44,998    89.2    \<0.001
  Radiotherapy                                              38,873          47.8        13,229    42.8    25,644    50.8    \<0.001
  Treatment II = other (neo) adjuvant systemic treatment                                                                    
  Other systemic treatment with aromatase inhibitor alone   3,886           4.78        1,141     3.69    2,745     5.44    \<0.001
  Other systemic treatment with chemotherapy alone          40,720          50.0        18,341    59.3    22,379    44.4    \<0.001
  Other systemic treatment with AI + CT                     16,493          20.3        3,611     11.7    12,882    25.5    \<0.001

Chi-square test; ^a^Student t test.

AI, aromatase inhibitor; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease, SD, standard deviation.

The mean follow-up periods were 4.71 (SD = 3.30) and 3.77 (SD = 3.17) years in the tamoxifen cohort and non-tamoxifen cohort, respectively (data not shown). At the end of the 12-year follow-up period, per the Kaplan--Meier analysis, the cumulative incidence of meningioma was significantly lower in the tamoxifen cohort than in the non-tamoxifen cohort (log-rank test: *P =* 0.02) ([**Figure 1**](#f1){ref-type="fig"}).

![Cumulative incidence curves of meningioma for breast cancer with and without tamoxifen use.](fphar-10-00674-g001){#f1}

The overall incidence density of meningioma was lower in the tamoxifen cohort than that in the non-tamoxifen cohort (1.77 versus 3.00 per 10,000 person-years) ([**Table 2**](#T2){ref-type="table"}). After adjusting for age, comorbidity, steroid use, statin use, thiazide diuretics use, treatment I, and treatment II, the adjusted hazard ratio (aHR) and 95% confidence interval (CI) for meningioma was 0.64-fold (95% CI = 0.40--1.02) for the tamoxifen users as compared with non-tamoxifen users.

###### 

Hazard ratios for meningioma among patients with breast cancer with and without using tamoxifen as revealed by the time-dependent regression model.

                                              Breast cancer without using tamoxifen   Breast cancer with using tamoxifen
  ------------------------------------------- --------------------------------------- ------------------------------------
  No. of meningioma                           35                                      42
  Person-years                                116,553                                 237,572
  Incidence rates (per 10,000 person-years)   3.00                                    1.77
  Crude HR (95% CI)                           1.00                                    0.59 (0.38, 0.93)\*
  Adjusted HR (95% CI)^\#^                    1.00                                    0.64 (0.40, 1.02)

CI, confidence interval; HR, hazard ratio ^\#^Adjusted for age, comorbidity, steroid use, statin use, thiazide diuretics use, treatment I, and treatment II. \*P \< 0.05.

Breast cancer patients receiving \>1,500 days of tamoxifen treatment exhibited significantly decreased meningioma risk compared with breast cancer patients who had not received tamoxifen treatment (aHR = 0.42, 95% CI = 0.19--0.91) ([**Table 3**](#T3){ref-type="table"}). Similar results were observed among breast cancer patients with different cumulative dosages of tamoxifen use; compared with breast cancer patients who did not use tamoxifen, the patients who used \>26,320 mg of tamoxifen had a significantly (aHR = 0.44; 95% CI = 0.22--0.88) lower risk of developing meningioma ([**Table 4**](#T4){ref-type="table"}).

###### 

Adjusted hazard ratio and incidence of meningioma by duration of tamoxifen therapy in patients with breast cancer with and without tamoxifen use.

  ----------------------------------------------------------------------------------------------------------
  Tamoxifen exposed         *n*      Event   Person-years   IR     Adjusted HR^‡^\       Adjusted HR^‡^\
                                                                   (95% CI)              (95% CI)
  ------------------------- -------- ------- -------------- ------ --------------------- -------------------
  Without using tamoxifen   30,929   35      116,553        3.00   1.00                  

  Duration on tamoxifen                                                                  

   ≤365 days                17,692   11      51,514         2.14   0.69 (0.34, 1.38)     1.00

   366--1,500 days          23,341   23      113,787        2.02   0.77 (0.44, 1.32)     1.00 (0.48, 2.07)

   \>1,500 days             9,409    8       72,271         1.11   0.42 (0.19, 0.91)\*   0.51 (0.20, 1.31)
  ----------------------------------------------------------------------------------------------------------

CI, confidence interval; HR, hazard ratio; IR, incidence density rates (per 10,000 person-years). ^‡^Adjusted for age, comorbidity, steroid use, statin use, and thiazide diuretics use, treatment I, and treatment II. \*P \< 0.05.

###### 

Adjusted hazard ratio and incidence of meningioma by cumulative dosage of tamoxifen use in patients with breast cancer with and without tamoxifen use.

  ----------------------------------------------------------------------------------------------------------
  Tamoxifen exposed         *n*      Event   Person-years   IR     Adjusted HR^‡^\       Adjusted HR^‡^\
                                                                   (95% CI)              (95% CI)
  ------------------------- -------- ------- -------------- ------ --------------------- -------------------
  Without using tamoxifen   30,929   35      116,553        3.00   1.00                  

  Dosage of tamoxifen                                                                    

   ≤4280 mg                 12,621   6       35,169         1.71   0.54 (0.23, 1.31)     1.00

   4281--12,980 mg          12,618   13      44,173         2.94   1.07 (0.55, 2.06)     1.88 (0.71, 4.97)

   12,981--26,320 mg        12,594   12      64,071         1.87   0.71 (0.36, 1.39)     1.15 (0.43, 3.09)

   \>26,320 mg              12,609   11      94,160         1.17   0.44 (0.22, 0.88)\*   0.68 (0.24, 1.87)
  ----------------------------------------------------------------------------------------------------------

CI, confidence interval; HR, hazard ratio; IR, incidence density rates (per 10,000 person-years). ^‡^Adjusted for age, aromatase inhibitor use, comorbidity, steroid use, statin use, thiazide diuretics use, treatment I, and treatment II. \*P \< 0.01.

[**Table 5**](#T5){ref-type="table"} illustrates the joint effect of aromatase inhibitor treatment and tamoxifen therapy on meningioma risk. Patients that received aromatase inhibitor treatment in addition to tamoxifen therapy did not have a significantly decreased risk of meningioma compared with patients without either treatment (aHR = 0.59, 95% CI = 0.31--1.15).

###### 

Joint effects of aromatase inhibitor use and tamoxifen use on the risk of meningioma in patients with breast cancer as revealed by the time-dependent regression model.

  --------------------------------------------------------------------------------------------
  Tamoxifen   Aromatase inhibitor   *N*      Event   Person-years   IR     Adjusted HR^‡^\
                                                                           (95% CI)
  ----------- --------------------- -------- ------- -------------- ------ -------------------
  No          No                    26,177   27      100,922        2.68   1.00

  No          Yes                   4,752    8       15,631         5.12   1.21 (0.54, 2.71)

  Yes         No                    34,815   28      156,553        1.79   0.69 (0.40, 1.18)

  Yes         Yes                   15,627   14      81,020         1.73   0.59 (0.31, 1.15)
  --------------------------------------------------------------------------------------------

CI, confidence interval; HR, hazard ratio; IR, incidence density rates (per 10,000 person-years). ^‡^Adjusted for age, comorbidity, steroid use, statin use, thiazide diuretics use, breast surgery, radiotherapy, and chemotherapy.

Discussion {#s4}
==========

This large study used a comprehensive national database to assess the meningioma risk in patients with previous diagnoses of breast cancer with or without tamoxifen use. In our study, tamoxifen users had a non-significantly (36%) lower risk of developing meningioma than did tamoxifen non-users. However, the decreased risk became significant when patients took tamoxifen treatment for longer than 1,500 days or took a cumulative dosage larger than 26,320 mg.

The breast cancer--meningioma relationship has been investigated for decades, but the results have been discordant. Several studies have detected a positive association between these two conditions ([@B39]; [@B16]; [@B27]; [@B36]; [@B37]; [@B30]). For example, Rao et al. found a strong association between breast cancer and meningioma, but only in women ([@B37]). Conversely, some studies have reported lower degrees of risk ([@B21]; [@B11]; [@B10]). Rather than a causal link, this association is likely related to shared common etiological factors, for example, shared genetic predisposition (e.g., variations in DNA repair polymorphisms) and endogenous and exogenous hormones ([@B3]; [@B44]).

Studies have suggested that hormonal factors may be involved in regulating the growth of meningioma ([@B18]; [@B43]; [@B25]; [@B24]; [@B5]; [@B23]). Researchers have indicated that hormone replacement therapy (especially estrogen-only) increases the risk of meningioma ([@B1]; [@B2]). Previous studies have found that meningiomas tend to express progesterone receptors more frequently (32.1%--86.3%) than estrogen receptors (7.1%--50%) ([@B27]; [@B43]; [@B24]), suggesting that progesterone and estrogen may influence tumor growth. Progesterone and estrogen antagonists may therefore inhibit tumor growth. An early study has found that selected meningiomas are subject to hormonal influence *in vitro*, and the inhibition of meningioma growth *in vitro* was observed by the antiprogesterone ([@B32]). Antiprogesteronal therapy and antiestrogenic therapy have been proposed for managing meningiomas ([@B29]; [@B14]; [@B15]; [@B22]); however, no definite role has been confirmed. Generally, tamoxifen binds to estrogen receptors and acts as partial antagonist or agonist depending on the type of target tissue ([@B46]). Two studies have focused on the treatment effect of tamoxifen in refractory, recurrent, or unresectable meningiomas, but neither indicated a favorable response of meningiomas to antiestrogenic therapy ([@B14]; [@B15]). Regardless of the null therapeutic effect, investigators have been interested in the prophylactic role of tamoxifen in meningioma among breast cancer patients. For example, Ji et al. evaluated the association of tamoxifen with meningioma in the Swedish population and reported that women with breast cancer who did not use tamoxifen had increased meningioma incidence, whereas in breast cancer patients treated with tamoxifen, the incidence was nearly the same as that of the general population, which suggests that tamoxifen likely plays in preventing meningioma development ([@B23]). Although the current study could not conclusively establish that for breast patients, tamoxifen treatment significantly decreases the risk of subsequent meningioma compared with non-tamoxifen treatment, the results were borderline significant, with a direction (protective role) consistent with their findings. The potential mechanisms account for this discrepancy of treatment and inverse association of tamoxifen in meningioma is still undetermined. We have to acknowledge that the information regarding mechanism of action and pharmacokinetic profiles of tamoxifen in meningothelial cells is scarce. Furthermore, the possible molecular mechanism(s) in the link between tamoxifen and meningioma is undetermined yet.

The NHI patient records provide a unique resource for a nationwide investigation of meningioma incidence among breast cancer patients. Other available and useful information was also retrieved for this study. The etiology of meningioma remains unclear, and ionizing radiation exposure and chemotherapy agents may be risk factors for meningioma development ([@B4]; [@B42]; [@B44]). The basic treatment information is available in the NHIRD, and we have adjusted these two factors in our analyses.

Tamoxifen in Taiwan is normally prescribed in breast cancer patients with a daily dose of 20 mg for a 5-year continuous treatment. Stratified analysis by treatment duration and cumulative dosage revealed that the inverse association of tamoxifen in meningioma among breast cancer patients was limited to those patients with long-term use (\>1,500 days) and dosage larger than 26,320 mg. The compliance of patients to tamoxifen may be related to the long-term use and total dosage, and it may imply that good compliance of patients to tamoxifen can reduce the risk of meningioma. Earlier studies from NHIRD evaluating the compliance of other drugs also supported this inference ([@B26]; [@B41]). We speculate that meningiomas are dependent on estrogen receptor (ER) as one of the reasons for the positive correlation between long-term tamoxifen use and reduced meningioma incidence. Presently, prescriptions that last longer than 5 years are uncommon as an adjuvant therapy for breast cancer. However, extending the duration of adjuvant treatment to 10 years has been previously reported to have a reduced risk of late breast cancer recurrence, thus improving survival ([@B12]). [**Table 4**](#T4){ref-type="table"} also displays a possible biphasic dose--response curve; however, the possible reasons accounting for this phenomenon are unclear. A previous paper has assessed hormone replacement therapy and the risk of meningioma and found that the risk of meningioma increases with duration of use of combined estrogen--progestagen within 1 year and ≥10 years, which also revealed a biphasic duration--response relationship ([@B1]). We acknowledge that the underlying mechanisms may be worth exploring in other studies. No significant joint effect was observed for treatment with tamoxifen and aromatase inhibitors. Similarly, no evidence was noted regarding whether the use of aromatase inhibitors affects the association between tamoxifen and meningioma. In addition, aromatase inhibitors without a similar association may be related to different mechanisms of anti-estrogen effect. Tamoxifen is known to antagonize activation function (AF)-2 in estrogen receptor (ER) but selectively activate estrogen receptor (ER)-AF1 and the AF1-mediated specific target genes, which are associated either with meningioma development or prevention. On the other hand, aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by aromatization. A previous study has found that there is a significantly increased risk of meningioma among men users of androgen analogues ([@B5]), and we speculate that this may partially account for the null protective effect of aromatase inhibitors in the development of meningioma.

To the best of our knowledge, this research is the first study with nationwide coverage in an Asian country to focus on consequent meningioma incidence among women with breast cancer taking tamoxifen. A major strength of the present study is that it used a nationwide population-based database for comprehensive analyses, which increases the statistical power of the study and generalizability. However, the database has several intrinsic limitations. First, the NHIRD does not contain detailed histology and phenotype information regarding breast cancer and meningioma; thus, we cannot control for breast cancer subtype when comparing the differences between the use of tamoxifen. We cannot evaluate the exact estrogen receptor and progesterone receptor statuses to further correlate the hormone effects on the possible relationship between tamoxifen and meningioma, either. Furthermore, grade of meningiomas cannot be differentiated from NHIRD, and it hinders us to assess if tamoxifen use or not has different effects on different grades of meningioma. Milano et al. found that women with both breast cancer and meningioma tended to have more advanced breast cancers and smaller-sized meningiomas compared with women having only one of these diagnoses ([@B30]); unfortunately, the current study cannot justify it. Second, precise brain MRI and CT information is unavailable in the NHIRD, and the resulting potential surveillance bias precludes a fair comparison of the risk of meningioma in breast cancer patients with that in the normal population. This might not be a big issue to be concerned since the central neural system (CNS) is not routinely screened in breast cancer patients, unless for patients with symptoms. On the other hand, meningioma is not systematically screened by brain MRI or CT, and the tumor may be found incidentally on an MRI or CT scan performed for other reasons. Third, information relevant to the lifestyle and behavior of the patients is scarce in the NHIRD, which made it difficult to adjust for the health behavior--related factors, such as smoking and unhealthy diets, which are well documented to increase the risk of certain cancers ([@B40]); moreover, the association of cigarette smoking and meningioma case status varies significantly by gender ([@B9]). Fourth, we realized that the comparator groups are not balanced in some factors as shown in [**Table 1**](#T1){ref-type="table"}; thus, we did the adjustment for these factors. However, residual confounding may still exist even after adjustment. Fifth, body mass index information is not recorded in the NHIRD, so we cannot adjust this factor in the analyses, either. Finally, tamoxifen user and non-user groups do not share cancer phenotypes. In general, patients who were prescribed tamoxifen were hormone receptor-positive, while those who were not prescribed tamoxifen were hormone receptor-negative. The former patients were known to have significantly better survival than the latter ([@B7]; [@B38]). The statistical data provided in this study could be misinterpreted since the comparison analysis in this specific setting can be compromised by other phenotypic variables. In addition, meningioma is typically a slow-growing tumor, and many cases never produce any symptoms. The risk of meningioma is higher in tamoxifen non-users partially because they were more likely to receive brain MRI or CT, for which they were easier to metastasize to brain compared with tamoxifen users. However, the current database cannot adjust for such confounding factor. Although some intrinsic limitations were imposed by the database, the data used in this study regarding the diagnoses of breast cancer and meningioma, the use of tamoxifen, as well as other treatments of breast cancer are highly trustworthy.

In summary, although primary hypothesis testing that tamoxifen use can decrease the risk of meningioma was not statistically significant, a trend of decreased risk of meningioma development among Taiwanese breast cancer survivors treated with tamoxifen was observed, especially for those with a long duration or a high dosage of tamoxifen therapy. The plausible mechanisms for the potential protective involvement of tamoxifen treatment in the meningioma development remain to be defined clearly. Although this could be explained partially by the hormone factor, additional comprehensive studies are warranted, and confirmatory evidence would be required before appropriate recommendations can be made.
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